Exporters seek favourable govt policies for export growth amid US tariff policy

MSMEs and Merchant Exporters have sought favourable domestic government policies to find alternative markets outside the US, considering the US policies of imposing penalty and tariffs in the near term for exempted commodity like pharma.

- 

US may also cite Intellectual Property (IP) and pricing issues, hitting pharma exports from India.

The US is India's largest overseas pharma market, with exports rising 21 per cent from USD 8.1 billion in FY24 to USD 9.8 billion in FY25. The latest figures mean 40 per cent of India's total pharma exports go to the US, remaining a key supplier of affordable medicines to the country.

This comes close on the heels of US President Donald Trump's announcement of 25 percent tariffs on imports from India. Further on this, US President is also ratcheting up the pressure on major drug makers to bring their US prices in line with the far lower ones available to patients in other countries.